Maravai LifeSciences (MRVI) Tops Q3 EPS by 3c

Maravai LifeSciences (NASDAQ: MRVI) reported Q3 EPS of $0.37, $0.03 better than the analyst estimate of $0.34. Revenue for the quarter came in at $191.3 million versus the consensus estimate of $195.4 million.

For earnings history and earnings-related data on Maravai LifeSciences (MRVI) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Piper Sandler on Fervo Energy (FRVO): 'Capital Access Supports Potential Upside'
• Goldman "broadly" raises estimates for LTL and truckload stocks